Abnormal Expression of Vimentin Intermediate Filaments in Human Lymphoid Cell Lines With Deletion or Translocation of the Distal End of Chromosome 8

The expression of vimentin, the major polypeptide of the intermediate filament (IFM) cytoskeleton of lymphoid cells, was studied in normal and malignant human lymphoid cell lines. Cells from 24 of 27 Burkitt's lymphoma cell lines (BLCL) were found to have an absent (16 lines) or decreased (8 li...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1984-07, Vol.73 (1), p.95-100
Main Authors: Dellagi, Koussay, Brouet, Jean-Claude, Portier, Marie-Madeleine, Lenoir, Gilbert M.
Format: Article
Language:English
Subjects:
Azacitidine - pharmacology
Biological and medical sciences
Burkitt Lymphoma - genetics
Cell Line
Chromosome Deletion
Chromosomes, Human, 6-12 and X
Fluorescent Antibody Technique
General aspects (metabolism, cell proliferation, established cell line...)
Humans
Intermediate Filament Proteins - genetics
Intermediate Filament Proteins - isolation & purification
Lymphocytes - drug effects
Lymphocytes - physiology
Medical sciences
Translocation, Genetic
Tumor cell
Tumors
Vimentin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of vimentin, the major polypeptide of the intermediate filament (IFM) cytoskeleton of lymphoid cells, was studied in normal and malignant human lymphoid cell lines. Cells from 24 of 27 Burkitt's lymphoma cell lines (BLCL) were found to have an absent (16 lines) or decreased (8 lines) expression of vimentin IFM. In contrast, non-Burkitt's malignant lymphoid cell lines (5 lines) and lymphoblastoid cell lines (LCL) derived from normal B-cells (45 lines) exhibited a well-developed vimentin IFM network. However, low expression of vimentin was also found in 3 LCL derived from patients with the Langer-Giedion syndrome, which is characterized by a deletion of the distal end of chromosome 8. Treatment of vimentin-negative BLCL and Langer-Giedion LCL with azacytidine led to a transient reexpression of vimentin.
ISSN:0027-8874
1460-2105
1460-2105
DOI:10.1093/jnci/73.1.95